Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EBT: 2020-2024

Historic EBT for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to -$57.1 million.

  • Xeris Biopharma Holdings' EBT rose 103.26% to $621,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 76.16%. This contributed to the annual value of -$57.1 million for FY2024, which is 10.08% up from last year.
  • As of FY2024, Xeris Biopharma Holdings' EBT stood at -$57.1 million, which was up 10.08% from -$63.5 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' EBT registered a high of -$57.1 million during FY2024, and its lowest value of -$122.7 million during FY2021.
  • Moreover, its 3-year median value for EBT was -$63.5 million (2023), whereas its average is -$72.2 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' EBT plummeted by 34.49% in 2021 and then surged by 33.91% in 2023.
  • Yearly analysis of 5 years shows Xeris Biopharma Holdings' EBT stood at -$91.2 million in 2020, then slumped by 34.49% to -$122.7 million in 2021, then grew by 21.71% to -$96.1 million in 2022, then skyrocketed by 33.91% to -$63.5 million in 2023, then climbed by 10.08% to -$57.1 million in 2024.